IDO1: An important immunotherapy target in cancer treatment
- 1 June 2017
- journal article
- review article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 47, 70-77
- https://doi.org/10.1016/j.intimp.2017.03.024
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalkInternational Immunopharmacology, 2013
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IdoNature Medicine, 2011
- Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell–like and Foxp3+ regulatory T cellsNature Immunology, 2010
- Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotionCancer Immunology, Immunotherapy, 2010
- Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of T H 17 to Regulatory T Cells in HIV DiseaseScience Translational Medicine, 2010
- Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active TargetJournal of the American College of Surgeons, 2009
- Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cellsNature Immunology, 2009
- Exploring the mechanism of tryptophan 2,3-dioxygenaseBiochemical Society Transactions, 2008
- Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenaseImmunology Letters, 2008
- Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenaseJCI Insight, 2007